Peptide education
Cagrilintide
Cagri · AM833 · NNC0174-0833
Cagrilintide is a long-acting analogue of amylin, a satiety hormone co-secreted with insulin, engineered for once-weekly metabolic research. It is best known as the amylin half of CagriSema, a fame that obscures its own evidence base: a 706-participant phase 2 dose-finding trial in adults with overweight or obesity. It is approved nowhere, and FDA says it cannot be used for routine compounding under federal law.
Cagrilintide is a legitimate drug candidate with real phase 2 human data, but its standalone evidence comes down to one obesity trial, and its legal status is unusually blunt: not approved, not lawful for routine compounding. Online Cagri products inherit neither the trial data nor a legal pathway.
Overview
Quick answer
Cagrilintide is the amylin-analogue component. CagriSema is cagrilintide plus semaglutide. A clinical-trial molecule, a coadministered combination study, a research-use vial, an online product listing, and a compounded product are not interchangeable just because they use the same name.
What is cagrilintide?
A lipidated, long-acting amylin analogue, also called AM833 or NNC0174-0833. Amylin signaling touches satiety, food intake, and gastric emptying, which is what put this molecule into obesity research.
What do people use or discuss it for?
Weight management, almost entirely. The direct evidence is one phase 2 obesity trial plus its registry record; most other mentions are as the amylin component of CagriSema or as an add-on idea in GLP-1 plateau discussions.
What route and schedule details are documented?
Once-weekly subcutaneous dosing across dose-finding arms from 0.3 mg to 4.5 mg in a 26-week phase 2 trial. Those numbers describe trial arms, and the work with semaglutide 2.4 mg is coadministration research, not cagrilintide-alone use.
Is it approved?
No. No FDA-approved cagrilintide label exists in the reviewed material, FDA states it has not been found safe and effective for any condition, and FDA says it cannot be used in compounding under federal law.
How is it different from CagriSema?
Cagrilintide is one molecule; CagriSema is that molecule plus semaglutide, studied as a fixed combination. The combination results explain the fame, but they are not standalone cagrilintide outcomes.
Reported practice
Commonly reported protocol
Research and gray-market amylin-analog discussion. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
A multicentre randomized, double-blind, placebo-controlled and active-controlled phase 2 dose-finding trial tested once-weekly cagrilintide in adults with overweight or obesity.
ClinicalTrials.gov lists NCT03856047 as completed with 706 actual participants and posted results for NNC0174-0833 in overweight or obesity.
The medicinal-chemistry paper describes cagrilintide as a stable, lipidated amylin analogue selected for longer exposure in clinical development.
A randomized phase 1b study evaluated concomitant multiple-dose cagrilintide with semaglutide 2.4 mg. That helps explain CagriSema interest, but it is not the same as cagrilintide-alone evidence.
FDA says cagrilintide cannot be used in compounding under federal law and has not been found safe and effective for any condition. FDA has also named Cagrilintide products in an online-product warning letter.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Cagrilintide is a weight-loss peptide. | The main standalone human evidence is a multicentre randomized phase 2 dose-finding trial of once-weekly cagrilintide in adults with overweight or obesity, plus the completed NCT03856047 registry record with posted results. | Cagrilintide was designed as a long-acting amylin analogue. Amylin-family signaling fits appetite, satiety, food-intake regulation, and gastric-emptying biology, which makes the weight-management program plausible. | Outside trials, reports are too scattered to identify a dependable standalone route, dose, frequency, or cycle. The clearest real-world signal is FDA action around online products and compounding. | Cagrilintide is an investigational weight-management candidate, not an approved drug, a basis for self-directed use, or evidence that online products are equivalent to the trial drug. |
| Cagrilintide is the same thing as CagriSema. | Cagrilintide has standalone phase 2 evidence, while CagriSema refers to the cagrilintide-plus-semaglutide combination. A phase 1b study tested multiple doses of cagrilintide with semaglutide 2.4 mg, which supports coadministration research while keeping the single-drug and combination programs separate. | Cagrilintide brings amylin-analogue biology. Semaglutide brings GLP-1 receptor agonism. The combined program pairs those systems, while cagrilintide remains the single amylin analogue. | Online discussion often shortens the naming, and CagriSema pages may pull cagrilintide into broader GLP-1 comparison talk. | Cagrilintide is the single amylin analogue; CagriSema is the combination with semaglutide. |
| Online cagrilintide products inherit the clinical-trial evidence. | No human trial verifies an online product, seller vial, compounded preparation, concentration, fill volume, sterility process, or storage chain. | Receptor biology only answers part of the question. Identity, purity, sterility, endotoxin, concentration, stability, and lawful manufacturing all affect what "cagrilintide" means in a product. | FDA has named Cagrilintide products in an online-product warning letter, and FDA separately states cagrilintide cannot be used in compounding under federal law. | The trial data describe controlled development material. Online product claims do not establish identity, quality, or regulatory status. |
| Cagrilintide is approved or legally compoundable. | No FDA-approved cagrilintide label was found in the reviewed material. FDA says cagrilintide has not been found safe and effective for any condition. | Amylin biology and phase 2 results can explain why a drug is studied, but they do not create approval or compounding eligibility. | Online product pages can make a drug candidate look commercially routine, but FDA materials point the other direction for cagrilintide. | Available FDA and trial sources do not back approval or routine compounding. It is investigational and outside routine compounding under FDA's stated position. |
| Cagrilintide shows that adding amylin to GLP-1 is always better. | A phase 1b cagrilintide-plus-semaglutide study shows early coadministration research. CagriSema materials can show why the combination became important, but single studies leave many comparator, population, dose, and long-term outcome questions open. | Pairing amylin and GLP-1 pathways is scientifically plausible because they act through different appetite and metabolic signals. | GLP-1 forums and product pages often turn combination logic into broad "stronger is better" language, especially around plateaus and appetite. | The combination rationale is real. Superiority claims need named trials, comparators, endpoints, and population details. |
Bottom line
Main takeaway
Cagrilintide is an investigational weight-management candidate, not an approved or legally compoundable peptide. The name you usually hear, Cagri, is mostly shorthand for a combination story.
Keep two ledgers separate: cagrilintide alone has one phase 2 obesity trial and its registry record, while the bigger numbers belong to the combination program with semaglutide.
The strongest sources are the Lancet phase 2 weight-management trial, NCT03856047 with posted results, the medicinal-chemistry paper, and FDA's compounding and warning-letter materials. Dose-arm details belong to the studies that ran them, not to product listings.
Identity
What it is
Cagrilintide is a modified amylin analogue built to fix native amylin's short life: a stable, lipidated molecule designed for once-weekly dosing, listed in PubChem with the formula C194H312N54O59S2.
Amylin biology sits next to the incretin system without duplicating it: satiety, food intake, gastric emptying, body weight. That made cagrilintide a credible standalone candidate and an obvious partner for a GLP-1 drug.
In practice the molecule lives in CagriSema's shadow. It appears alone in one phase 2 program, in coadministration research with semaglutide, and in online product claims that carry a much thinner evidence trail and no lawful compounding route.
How people talk about it online
Cagrilintide shows up online as Cagri, as the amylin half of CagriSema, or as a proposed add-on when GLP-1 progress stalls. The interest is real; the standalone use patterns are not.
Clinic and forum Cagri routines imitate the CagriSema concept with separate vials, and the posts never converge on one documented route, amount, schedule, or course length.
On the product side the regulator has been explicit: FDA named online Cagrilintide products in a warning letter and states that routine compounding of this molecule is not lawful.
Use context
Routes, doses, and cycle patterns
The most reliable use details are study descriptions: once-weekly subcutaneous cagrilintide in a phase 2 weight-management trial, a completed NCT03856047 registry record, and early coadministration research with semaglutide 2.4 mg. Those details explain the trial arms; they are different from clinic or forum Cagri routines.
Human studies and product labels
Single-agent phase 2 weight-management trial
- Purpose
- Weight management in adults with overweight or obesity
- Context
- Randomized phase 2 dose-finding trial
- Route
- Subcutaneous
- Amount
- Dose-finding arms in the named phase 2 trial; not instructions for use
- Frequency
- Once weekly
- Duration
- 26 weeks, with follow-up to week 32
This is the central standalone human trial for cagrilintide. It supports the weight-management research case and shows dose-finding arms, but it does not create an approved label or a real-world use schedule.
NCT03856047 completed registry record
- Purpose
- Trial status and results context for NNC0174-0833
- Context
- ClinicalTrials.gov completed phase 2 registry with posted results
- Route
- Subcutaneous in the completed trial record
- Amount
- Dose-finding arms in the registry record; not instructions for use
- Frequency
- Once weekly
- Duration
- 26 weeks, with follow-up to week 32
The registry documents trial completion, 706 actual participants, and posted results. It helps confirm the studied population, dose arms, duration, and posted results; it does not show how non-trial or online products behave.
Cagrilintide with semaglutide 2.4 mg
- Purpose
- Early combination and CagriSema development context
- Context
- Randomized phase 1b coadministration study
- Route
- Subcutaneous in the coadministration study
- Amount
- 0.16 to 4.5 mg cagrilintide with semaglutide 2.4 mg
- Frequency
- Once weekly in the coadministration study
- Duration
- 20 weeks
This coadministration study explains why cagrilintide became part of combination research. It remains separate from the single-agent phase 2 trial.
Real-world discussion
Research and gray-market amylin-analog discussion
- Purpose
- Weight-loss combination discussion
- Context
- Vendor listings, forums, and protocol blogs
- Route
- Subcutaneous injection
- Amount
- Community and vendor discussion commonly references the 2.4 mg weekly amount from the obesity trial program. Reported real-world amounts cluster around 0.5 to 2.4 mg weekly, often alongside a GLP-1.
- Frequency
- Once weekly in trial-derived discussion
- Duration
- Multi-week to multi-month runs in community logs
Cagrilintide is investigational and not approved anywhere, so all non-trial supply is unverified. Community use is usually framed as imitating the CagriSema concept with separate vials. Informational context, not advice.
What varies
- Goal: cagrilintide-alone weight-management research is different from CagriSema combination research.
- Route: phase 2 and registry descriptions use subcutaneous administration; online product wording cannot confirm that the material matches the clinical-trial drug.
- Amount: 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, and 4.5 mg appear as cagrilintide arms in the phase 2 dose-finding trial; those numbers describe trial arms, not instructions for use.
- Frequency: once weekly appears in the phase 2 trial; forum and clinic frequencies are not documented in the cited cagrilintide materials.
- Product: identity, sterility, endotoxin, concentration, storage, and legal status are separate from a molecule name.
Human data
Human evidence
The standalone human record is one well-run phase 2 program: a randomized, double-blind, placebo and active-controlled dose-finding trial of once-weekly cagrilintide in adults with overweight or obesity, confirmed by a completed registry entry with 706 participants and posted results. The phase 1b study with semaglutide 2.4 mg supplies combination context, not single-agent efficacy. Past that, the human evidence is regulatory: FDA states the molecule has not been found safe and effective for any condition and has named online Cagrilintide products in a warning letter.
Evidence maturity
Cagrilintide has real phase 2 human weight-management data, but it remains investigational with no approved label and no lawful compounding route.
Medicinal-chemistry work produced a stable, lipidated long-acting amylin analogue built for once-weekly metabolic research.
A randomized phase 1b study tested cagrilintide coadministered with semaglutide 2.4 mg, setting up the CagriSema rationale.
A 706-participant randomized dose-finding trial tested once-weekly cagrilintide in adults with overweight or obesity, with posted registry results.
No approved label exists anywhere, and FDA says cagrilintide has not been found safe and effective for any condition and cannot be used in routine compounding.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Once-weekly cagrilintide phase 2 weight-management trial | Adults with overweight or obesity | Multicentre randomized, double-blind, placebo-controlled and active-controlled phase 2 dose-finding trial | Investigational product | The trial is the main peer-reviewed human study for cagrilintide as a standalone weight-management candidate, with once-weekly 0.3 mg through 4.5 mg subcutaneous dose arms over 26 weeks and follow-up to week 32. | Phase 2 evidence is not an approval label. Dose-arm details are trial context, not a schedule to copy. | Moderate |
| NCT03856047 | People with overweight or obesity in the NNC0174-0833 dose-finding trial | Completed phase 2 ClinicalTrials.gov record with posted results | Investigational product | The registry lists the study as completed with 706 actual participants and posted results. | The registry confirms trial status and posted results; it does not provide consumer instructions. | Moderate |
| Cagrilintide plus semaglutide phase 1b | Weight-management development population in an early coadministration study | Randomized phase 1b coadministration study | Investigational combination research | Multiple doses of cagrilintide were studied with semaglutide 2.4 mg, supporting early combination-development context. | Coadministration data do not merge into a cagrilintide-alone efficacy claim or an informal CagriSema protocol. | Weak to moderate |
| Cagrilintide development chemistry | Preclinical and translational development context | Medicinal-chemistry and structure-activity source | Investigational molecule design | The paper explains the stable, lipidated, long-acting amylin-analogue design that led to clinical development. | Chemistry explains why the molecule was built. Weight outcomes need human trial data. | Preclinical |
| FDA compounding and online-product materials | Clinical-development and online-product comparison context | FDA safety and enforcement communications | Online-product and compounding-enforcement context | FDA states cagrilintide cannot be used in compounding under federal law and has named Cagrilintide products in an online-product warning letter. | FDA materials are not batch tests for every seller, but they are strong enough to reject routine approval, compounding, or equivalence claims. | Strong |
Cautions
Safety and unknowns
- Cagrilintide does not have an approval label, so label-level contraindications, warnings, monitoring instructions, and special-population language have not been packaged into a public approval label.
- Phase 2 and phase 1b studies can describe tolerability in studied populations, but rare events, long-term outcomes, durability after stopping, and safety in broader patient groups remain open.
- Amylin-pathway and GLP-1-adjacent weight-management studies often raise gastrointestinal tolerability questions, but cagrilintide-specific public safety language belongs with named trials and labels when available.
- Combination evidence with semaglutide brings additional questions because semaglutide has its own label-level safety background. That background belongs in combination or component context, not cagrilintide-alone claims.
- Online or compounded products add risks outside the trial record: wrong identity, wrong concentration, missing sterility controls, endotoxin, unstable shipping, storage problems, and unclear chain of custody.
Product quality
A vial label is only a starting point
FDA has said cagrilintide cannot be used in compounding under federal law and has not been found safe and effective for any condition.
FDA warning letters name online Cagrilintide products without establishing approval, sterile manufacturing, correct identity, or equivalence to the trial product.
Cagrilintide is a large modified peptide. For any injectable peptide, the molecule name still needs lot-level support for identity, purity, sterility, endotoxin, concentration, storage, and shipping conditions.
Identity
"Cagrilintide" on a product listing or vial still needs product identity and characterization support.
Sterility and endotoxin
Injectable-product safety depends on sterile manufacturing and endotoxin control, not just purity language.
Concentration
Weight-management peptides are often discussed in small milligram or microgram quantities, so concentration errors can change exposure.
Legal status
FDA's stated position on cagrilintide and compounding is a direct status issue for the product, not a minor labeling detail.
Mechanism
How it is proposed to work
Amylin is a hormone involved in satiety and meal-related metabolic signals. Cagrilintide was engineered as a long-acting amylin analogue, so the basic idea is to extend amylin-like signaling in a way that can be studied for appetite and body-weight effects.
The medicinal-chemistry source describes cagrilintide as a stable, lipidated analogue selected for longer exposure than native amylin.
The weight-management interest comes from pairing that long-acting amylin design with outcomes testing in adults with overweight or obesity.
Combination research with semaglutide adds GLP-1 biology to the picture, but the cagrilintide-alone mechanism remains amylin-analogue signaling.
Cagrilintide is a long-acting amylin analog. Amylin is a pancreatic hormone co-secreted with insulin that acts on area-postrema receptors to reduce appetite and slow gastric emptying: a complementary satiety pathway to the incretins, which is the logic of the CagriSema combination.
FAQ
Common questions
Is Cagrilintide FDA-approved?
No. Cagrilintide is investigational. FDA states that cagrilintide has not been found safe and effective for any condition and cannot be used in compounding under federal law.
Is Cagrilintide the same thing as CagriSema?
No. Cagrilintide is the amylin-analogue component. CagriSema refers to coadministered cagrilintide plus semaglutide, which has its own evidence; merging it into a single-agent Cagrilintide claim would be misleading.
Do online Cagrilintide products inherit the clinical-trial evidence?
No. Trial evidence comes from controlled development settings. FDA has separately named Cagrilintide products offered online as unapproved new-drug concerns, so product identity and quality remain separate questions.
Details
Technical details
Sources
References
- 1.
doi:10.1016/S0140-6736(21)01751-7 PMID:34798060 Accessed 2026-06-09.
Primary peer-reviewed phase 2 trial for once-weekly cagrilintide in adults with overweight or obesity; supports the single-agent human weight-management evidence.
- 2.
ClinicalTrials.gov. NCT03856047 ClinicalTrials.gov record for NNC0174-0833 weight management 2024.
NCT03856047 Accessed 2026-06-09.
Completed phase 2 dose-finding registry record with 706 actual participants and posted results for NNC0174-0833 in overweight or obesity.
- 3.
PubMed. Development of Cagrilintide, a Long-Acting Amylin Analogue 2021.
doi:10.1021/acs.jmedchem.1c00565 PMID:34288673 Accessed 2026-06-09.
Medicinal-chemistry source for the stable, lipidated long-acting amylin-analogue design and clinical-development rationale.
- 4.
doi:10.1016/S0140-6736(21)00845-X PMID:33894838 Accessed 2026-06-09.
Randomized phase 1b coadministration study; useful for separating cagrilintide-alone evidence from CagriSema combination evidence.
- 5.
FDA. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss 2026.
Accessed 2026-06-09.
FDA page states that cagrilintide cannot be used in compounding under federal law and has not been found safe and effective for any condition.
- 6.
FDA. Prime Sciences warning letter 2026.
Accessed 2026-06-09.
FDA warning letter naming Cagrilintide products offered online and describing unapproved new-drug and injectable-product safety concerns.
- 7.
PubChem. PubChem Compound Summary for Cagrilintide 2026.
Accessed 2026-06-09.
Chemistry source for cagrilintide CID 171397054, molecular formula C194H312N54O59S2, and molecular-weight context.